Results 21 to 30 of about 28,321 (229)

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

open access: yesPLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak   +8 more
doaj   +1 more source

Feline primary erythrocytosis: a multicentre case series of 18 cats [PDF]

open access: yes, 2018
A retrospective multicentre case series of feline primary erythrocytosis (PE) was evaluated. The aim was to gain better understanding of disease presentation and progression to guide management and prognostication. Case records were assessed for evidence
Balazs Szladovits   +7 more
core   +2 more sources

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

open access: yesHaematologica, 2009
Background The JAK2V617F mutation has been associated with constitutive and enhanced activation of neutrophils, while no information is available concerning other leukocyte subtypes.Design and Methods We evaluated correlations between JAK2V617F mutation ...
Lisa Pieri   +7 more
doaj   +1 more source

Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]

open access: yes, 2017
We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene   +5 more
core   +1 more source

Erythematous Macular Eruption in an Older Woman [PDF]

open access: yes, 2019
A white woman in her 70s with advanced Alzheimer disease was referred to the hematology clinic for evaluation of a high hemoglobin level (169 g/L; normal range, 120-160 g/L) and red blood cell count (5.67 × 1012/L; normal range, 3.8-4.8 × 1012/L) as well
Kernohan, Neil   +2 more
core   +2 more sources

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms [PDF]

open access: yes, 2015
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,
Aranaz, P.   +99 more
core   +5 more sources

Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics

open access: yesActa Dermato-Venereologica, 2018
Aquagenic pruritus is one of the main clinical features of polycythemia vera. The aim of this study was to analyse the clinical characteristics of aquagenic pruritus.
Edyta Lelonek   +3 more
doaj   +1 more source

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report

open access: yesJournal of Medical Case Reports, 2018
Background Polycythemia vera is a myeloproliferative disease that sometimes evolves to myelofibrosis, causing splenomegaly and neutropenia. In this case report, we describe a patient with polycythemia vera and unexplained neutropenia who later turned out
Andreas Hanssønn Habberstad   +6 more
doaj   +1 more source

Mouse models of myeloproliferative Neoplasms: JAK of all grades. (Review) [PDF]

open access: yes, 2011
In 2005, several groups identified a single gain-of-function point mutation in the JAK2 kinase that was present in the majority of patients with myeloproliferative neoplasms (MPNs).
Li, J.   +7 more
core   +2 more sources

Concurrent Polycythemia Vera with Newly Diagnosed Multiple Myeloma: Case Report and Literature Review

open access: yesJournal of Inflammation Research, 2023
Jing Yuan, Xuan Liu, Zhenzhen Wang, Liyuan Li, Fuxu Wang Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People’s Republic of ChinaCorrespondence: Fuxu Wang, Department of Hematology, The Second ...
Yuan J, Liu X, Wang Z, Li L, Wang F
doaj  

Home - About - Disclaimer - Privacy